Onconetix Stock Scheduled to Reverse Split on Tuesday, September 24th (NASDAQ:ONCO)

Shares of Onconetix, Inc. (NASDAQ:ONCO) are going to reverse split on the morning of Tuesday, September 24th. The 1-40 reverse split was announced on Friday, September 20th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 23rd.

Onconetix Stock Down 28.7 %

NASDAQ:ONCO opened at $0.08 on Friday. Onconetix has a 12-month low of $0.08 and a 12-month high of $0.62. The company’s 50-day moving average is $0.14 and its two-hundred day moving average is $0.15. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.09 and a current ratio of 0.10.

Onconetix (NASDAQ:ONCO) last posted its quarterly earnings data on Thursday, August 29th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $0.71 million for the quarter.

Institutional Investors Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned 1.37% of Onconetix at the end of the most recent quarter. Institutional investors and hedge funds own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.